Gilead Sciences

Pharmaceutical Executive | February 12, 2018

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada. The United States case is filed in the US District Court for the District of Delaware and the patent is US patent No. 8,129,385. The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282....

fiercepharma | March 27, 2018

Gilead Sciences completely transformed its business model last year when it got into the cell-therapy field by buying CAR-T developer Kite Pharma for $11.9 billion. Its top line won't be transformed so quickly. Kite’s cancer CAR-T, approved by the FDA in October, faced early reimbursement hurdles that hampered pickup. Declining sales in the company’s hepatitis C franchise drove Gilead’s total revenues for 2017 down 14% to $26.1 billion. But those challenges didn’t sto...

Prnewswire | April 19, 2019

Eight patients who took the popular HIV/AIDS drug Truvada and similar tenofovir-based drugs have sued Gilead Sciences, Inc., claiming the giant pharmaceutical company deliberately withheld a much safer version of these drugs from the market for more than a decade in a patent-timing scheme to maximize profits. As a result, "hundreds of thousands of HIV-infected patients experienced serious, permanent and sometimes fatal complications that may have been avoided had the company been honest abo...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...